期刊文献+

干扰素应答因子1对不同p53状态骨肉瘤凋亡的调节作用 被引量:1

The effect of interferon regulatory factor-1 on apoptosis regulation in osteosarcomawith differentp53 status
原文传递
导出
摘要 目的观察干扰素应答因子1(IRF-1)基因对不同p53状态骨肉瘤细胞凋亡的调节作用,并探讨其机制。方法利用u20s(p53^+/+)和Saos2(p53^-/-)骨肉瘤细胞作为研究模型,用不同剂量阿霉素处理后,Western blot检测IRF-1表达的变化。进一步通过过表达IRF-1基因或敲除IRF-1基因,检测其对骨肉瘤细胞凋亡的影响。并通过实时定量逆转录聚合酶链反应(RT-qPCR)法检测IRF-1对p53下游靶基因B细胞淋巴瘤/白血病-2相关x蛋白(bax)和p21的调节作用。结果不同剂量阿霉素处理U20S和Saos2后,Westernblot结果显示IRF-1的表达明显增高。进一步过表达IRF-1后,乳酸脱氢酶(LDH)法检测细胞死亡率明显增高(P〈0.05);干涉IRF-1基因后,全量LDH检测细胞死亡率则明显降低(P〈0.05)。RT-qPCR检测显示,IRF-1对p53下游靶基因bax和p21在p53^-/-SaOS-2细胞中具有明显的促进作用(P〈0.05),而对于p53^+/+U20S中的作用并不明显(P〉0.05)。结论IRF-1可通过调节p53下游靶基因bax和p21的表达,从而显著促进阿霉素诱导的骨肉瘤细胞凋亡。 Objective Detect the effects of interferon regulatory factor-1 ( IRF-1 ) gene on the ap optosisregulation in osteosarcoma with different p53 status and disclose the underlying mechnisms prelimina rily. Methods To observe the effects of IRF-1 gene on the apoptosis effects induced by chemotherapeutic agent adriamycin in steosarcoma with different p53 status, p53^+/+ U2OS and p53^-/-SaOS-2 were used. Western blotting analysis was firstly used to detect the expression of IRF-1 protein in adriamycin treated p53 ^+/+ U2OS and p53^ -/- SaOS-2 cells. And then IRF-1 gene was further overexpressed or knocked out for further detection the apoptosis effect induced by adriamycin respectively. Meanwhile, the target genes of 1953, B cell lymphoma/leukemia-2 associated X protein (bax) and p21, were detected by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR). Results Western blotting showed that the expres sion of IRF-1 has been improved significantly when p53 ^+/+ U2OS and p53 ^-/- SaOS-2 were treated with ad riamycin for 24 h. The significant increase in the death rate of cells has been detected by the release of lac tate dehydrogenase ( LDH ) Activity ( P 〈 0. 05 ). When IRF-1 gene were overexpressed with transient transfection, adriamycin-induced apoptosis effect were increased significantly (P 〈 0. 05 ), while the knockdown of IRF-1 gene by small interfering RNA ( siRNA ) transfection were decreased significantly ( P 〈 0.05 ). RT-qPCR were used to further detected the expression of downstream target genes bax and p21, which do great favor to p53-dependent apoptosis. The results showed that bax and p21 were both up- regulated significantly in p53^-/-osteosarcoma cells (P 〈 0. 05 ) , but not observed in p53 ^+/+ osteosarcoma cells ( P 〉 0.05 ). Conclusion IRF-1 plays a crucial role in adrymycin induced apoptosis by modulating p53 target genes, especially to the cancer cells with p53 gene deficient.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第4期835-837,共3页 Chinese Journal of Experimental Surgery
关键词 干扰素应答因子1 骨肉瘤细胞 P53 凋亡 Interferon regulatory factor-1 Osteosarcoma cells p53 Apoptosis
  • 相关文献

参考文献5

  • 1Tanaka N,Ishihara M, Lamphier MS, et al. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage [ J ]. Nature, 1996,382 (6594) :816-818.
  • 2Wunder JS,Gokgoz N,Parkes R,et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study [ J ]. J Clin Oncol, 2005,23 (7) : 1483-1490.
  • 3吴强,杨述华.p53基因在骨肉瘤中的研究进展[J].国外医学(骨科学分册),2002,23(4):226-229. 被引量:2
  • 4Overhohzer M, Rao PH,Favis R,et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomie instabil- ity[J]. Proe Natl Aead Sei U S A,2003,100(20) :11547-11552.
  • 5Ning Y, Riggins RB, Mulla JE, et al. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB,BCL2 family members, and signaling to caspase-depend- ent apoptosis [ J]. Mol Cancer Ther,2010,9 (5) : 1274-1285.

二级参考文献22

  • 1Guo W, Wang X, Feng C et al. Chin Med J Engl, 1996; 109(10): 752~755
  • 2Toguchida J, Yamaguchi T, Ritchie B et al. Cancer Res, 1992; 52(22): 6194~6199
  • 3Ueda Y, Dockhorn DB, Blasius S et al. J Cancer Res Clin Oncol, 1998; 119(3): 172~178
  • 4Longhi A, Benassi MS, Molendini L et al. Oncol Rep, 2001; 8(1): 131~136
  • 5Grote HJ, Schneider-Stock R, Neumann W et al. Virchows Arch, 2000; 436(5): 494~497
  • 6Lopes MA, Nikitakis NG, Ord RA et al. Oral Oncol, 2001; 37(7): 566~571
  • 7Lonardo F, Ueda T, Huvos AG et al. Cancer, 1997; 79(8): 1541~1547
  • 8Miller CW, Aslo A, Won A et al. J Cancer Res Clin Oncol, 1996; 122(9): 559~565
  • 9Wang H, Zeng X, Oliver P et al. Int J Oncol, 1999; 15(4): 653~660
  • 10Nishikawa T, Yamamoto T, Mizuno K et al. Nippon Seikeigeka Gakkai Zasshi, 1997; 68(5): 400~406

共引文献1

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部